Xuxi Zhang

Baseline and Follow ‐ up (4 years) # IG: 647 CG: 616 Duration of diabetes (year): 10.1±7.0 HbA1c (%): 8.4±1.1 Blood pressure (mm Hg): Systolic: 138.0±16.7 Diastolic: 76.3±10.5 Total Cholesterol (mg/dl): LDL: 107.4±37.0 HDL: 46.3±12.8 BMI: 32.7±5.7 Without diabetic retinopathy (%): 50.9 Duration of diabetes (year): 10.3±7.5 HbA1c (%): 8.2±1.0 Blood pressure (mm Hg): Systolic: 139.0±14.7 Diastolic: 76.8±9.9 Total Cholesterol (mg/dl): LDL: 104.1±33.5 HDL: 46.1±13.8 BMI: 32.2±5.3 Without diabetic retinopathy (%): 47.9 Intensive systolic blood ‐ pressure control (<120 mm Hg) vs. Standard systolic blood ‐ pressure control (<140 mm Hg) Lipid study Baseline and Follow ‐ up (4 years) # IG: 806 CG: 787 Patients with type 2 diabetes Female (%): 30.6 Mean age: 61.9±6.2 Duration of diabetes (year): 9.7±6.8 HbA1c (%): 8.2±1.0 Blood pressure (mm Hg): Systolic: 131.5±17.0 Diastolic: 73.7±10.5 Total Cholesterol (mg/dl): LDL: 96.5±29.7 HDL: 38.6±7.8 BMI: 32.3±5.5 Without diabetic retinopathy (%): 53.2 Patients with type 2 diabetes Female (%): 32.3 Mean age: 61.5±6.5 Duration of diabetes (year): 9.8±7.2 HbA1c (%): 8.2±1.0 Blood pressure (mm Hg): Systolic: 131.1±17.5 Diastolic: 73.6±10.5 Total Cholesterol (mg/dl): LDL: 97.0±30.1 HDL: 38.5±7.9 BMI: 32.6±5.4 Without diabetic retinopathy (%): 50.6 RCT USA and Canada Lipid ‐ control intervention Fenofibrate (160mg/day), to decrease triglyceride levels and to increase HDL cholesterol levels vs. Placebo Kumamoto, 1995 Primary ‐ prevention cohort (no retinopathy) Baseline and follow ‐ up (6 years) † :IG:26 CG: 25 Patients with type 2 diabetes Female (%): 46.2 Mean age: 47±9 Duration of diabetes (year): 6.2±5.0 HbA1c (%): 9.2±1.8 Blood pressure (mm Hg): Systolic: 119±9 Diastolic: 69±6 Total Cholesterol (mg/dl): LDL:  ‐  Patients with non ‐ insulin ‐ dependent diabetes Female (%): 52 Mean age: 49±14 Duration of diabetes (year): 6.7±5.3 HbA1c (%): 8.9±1.8 Blood pressure (mm Hg): Systolic: 121±14 Diastolic: 70±7 Total Cholesterol (mg/dl): RCT Japan Glycemic ‐ control intervention Multiple insulin injection treatment vs. Conventional insulin injection treatment 7 181 Prevention and control of diabetic retinopathy